An experimental therapy designed to mimic vitamin B12 and deliver a toxic molecule to tumor cells showed promise as a potential treatment for an aggressive…
Glioma
A Phase 1 clinical trial testing TLX101-Tx, Telix Pharmaceuticals‘ experimental treatment for glioblastoma (an aggressive form of glioma), has completed enrollment. The study,…
In an early clinical trial testing the novel therapy Alpha DaRT for recurrent glioblastoma, the first three patients given the radiation treatment all showed a…
The first participant has been dosed in a clinical trial testing the experimental therapy GLIX1 in people with recurrent or progressive glioblastoma, an aggressive form…
Advocates across North America are launching a wave of fundraisers and educational campaigns this week as May kicks off Brain Tumor Awareness Month. From high-profile…
The European Commission has approved Ipsen’s oral therapy Ojemda (tovorafenib) to treat certain children with pediatric low-grade glioma (pLGG).
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to plixorafenib as a potential treatment for adults with high-grade gliomas carrying…
The U.S. Food and Drug Administration (FDA) has agreed to review an application from Telix Pharmaceuticals seeking approval of TLX101-Px, the company’s experimental imaging…
The U.S. Food and Drug Administration (FDA) has awarded orphan drug designation to the experimental radiation therapy rhenium Re186 obisbemeda — slated to be marketed…
GLIX1, a treatment for recurrent and progressive glioblastoma and other high-grade gliomas, has begun human testing in a Phase 1/2a clinical trial, said…
Recent Posts
- As a caregiver, I’ve learned to read my mum’s daily forecast
- Short radiation course may ease painful myeloma bone lesions
- Nearly 70% of those given approved myeloma therapy alive 5 years later
- Latest AACR progress report on myeloma is a superpower of good news
- FDA green lights first-in-human study of infusion leukemia treatment